New UN Program Hopes to Begin Large-Scale Trials of AIDS Vaccines in 1996

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

GENEVA, Switzerland--A newly established United Nations AIDS program based in Geneva has announced plans to initiate large-scale clinical trials of two HIV vaccines as early as mid-1996, probably in Brazil and Thailand. Dr. Peter Piot, chief of research at the World Health Organization's Global Program on AIDS, will head the new group, which will involve six UN agencies.

GENEVA, Switzerland--A newly established United Nations AIDS programbased in Geneva has announced plans to initiate large-scale clinicaltrials of two HIV vaccines as early as mid-1996, probably in Braziland Thailand. Dr. Peter Piot, chief of research at the World HealthOrganization's Global Program on AIDS, will head the new group,which will involve six UN agencies.

From 3,000 to 20,000 volunteers will participate in the trialsin the two developing countries, Dr. Piot said. The UN group plansto conduct behavioral research and pilot studies in an effortto ensure that volunteers do not engage in risky behavior duringthe trial because they think the vaccine is protecting them.

Last October, a WHO advisory committee recommended that the organizationgo ahead with plans for large-scale HIV vaccine trials. Such trialswere rejected last June by a US panel.

With an estimated 17 million people infected worldwide, even avaccine with a low degree of efficacy would prove valuable instemming the epidemic, the WHO advisory committee argued.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content